Indication

Gray-Zone Lymphoma

2 clinical trials

4 drugs

Clinical trial

A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Status: Active (not recruiting), Estimated PCD: 2023-05-26

Drug

Drug

Clinical trial

A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)

Status: Active (not recruiting), Estimated PCD: 2025-06-30

Drug

Drug